Moximed Raises $40 Million to Advance World’s First Implantable Shock Absorber for Knee Osteoarthritis

FREMONT, Calif.–(BUSINESS WIRE)–Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced $40 million in Series C equity and debt financing. The round was led by Advent Life Sciences and also included returning investors New Enterprise Associates (NEA), Future Fund, Vertex Healthcare, Gilde … [Read more…]

Physicians Group Files U.S. Supreme Court Brief in Favor of California’s Proposition 12

Stressed farmed animals pose a significant public health risk, doctors say WASHINGTON–(BUSINESS WIRE)–The Physicians Committee for Responsible Medicine, a national public health nonprofit of more than 17,000 doctor members, filed an amicus brief with the U.S. Supreme Court on Monday, Aug. 15, in support of California’s Proposition 12, a law establishing confinement standards for pigs … [Read more…]

FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in … [Read more…]

LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer

First PARP inhibitor to demonstrate clinical benefit in combination with a new hormonal agent irrespective of homologous recombination repair (HRR) gene mutations WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s supplemental New Drug Application (sNDA) for LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of … [Read more…]

Restore Hyper Wellness Ranks No. 411 on the 2022 Inc. 5000 Annual List

Restore Moves Up From No. 426 in 2021 to No. 411 in 2022 on the Inc. 5000 Ranking of America’s Fastest-Growing Private Companies AUSTIN, Texas–(BUSINESS WIRE)–Today, Inc. revealed that Restore Hyper Wellness (Restore), the leading provider of proactive wellness services, ranked No. 411 on its annual Inc. 5000 list, the most prestigious ranking of the … [Read more…]

TransMed7, LLC Announces First Clinical Use of Heron Soft Tissue Biopsy Devices for Commercial Launch

PORTOLA VALLEY, Calif.–(BUSINESS WIRE)–TransMed7, LLC announced today that the “First in Human” clinical case of the commercial production version of a Heron™ XPS device (a member of the new Heron™ family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC®) Soft Tissue Biopsy devices) was successfully performed by Dr. Edgar Staren, a surgical oncologist with the … [Read more…]

Babylon Responds to Speculations

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE: BBLN) (“Babylon” or the “Company”), one of the world’s fastest-growing digital healthcare companies, released a statement yesterday addressing the M&A speculation and a more than 20% increase in the Company’s stock price at one point during the trading day that led to the New York Stock Exchange’s … [Read more…]

High Potency APIs Global Market Opportunities And Strategies 2022: Rise in the Number of Cancer Cases, Growing Focus on Precision Medicine and Increasing Ageing Population to Propel Future Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “High Potency APIs Global Market Opportunities And Strategies To 2031” report has been added to ResearchAndMarkets.com’s offering. The global high potency APIs market reached a value of nearly $19,772.2 million in 2021, having grown at a compound annual growth rate (CAGR) of 5.2% since 2016. The market is expected to grow from $19,772.2 … [Read more…]

VISEON Inc. Receives EU Quality Management Certification and CE Mark under the Medical Device Regulation (MDR)

IRVINE, Calif.–(BUSINESS WIRE)–Today Viseon Inc. announced that it has received Quality Management and CE Mark Certification for their MaxView® System device under the new MDR. The EU MDR is the set of regulations that governs the worldwide production and European distribution of medical devices. Compliance with this regulation is mandatory for medical device companies to … [Read more…]

SleepScore Labs Makes Inc. 5000 List of Fastest-Growing, Privately-Owned Companies in America

SleepScore ranks 417th out of 5,000 companies, 65th in California CARLSBAD, Calif.–(BUSINESS WIRE)–SleepScore Labs, the company behind the science of sleep improvement, today announced it has made the prestigious Inc. 5000 Fastest Growing Companies in America list for the first time. SleepScore ranked 417th out of 5,000 companies, and was recognized as 65th in California, … [Read more…]